

Contents – Summary

Foreword	V
Preface	VII
Contributors to the Fifth Edition	XIII
Contents	XIX
Introduction to the 5th Edition	1
1 Patentable Subject Matter/Industrial Applicability/Utility: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	6
1.1 Patentable Subject Matter/Industrial Applicability: EPO (Articles 52 and 53 EPC1973, Articles 52, 53 and 54(5) EPC2000, the EU Directive 98/44/EC of July 6, 1998 and its Implementation by the EPO)	6
1.2 Patentable Subject Matter/Utility: US (35 U. S. C. § 101 (1984))	20
1.3 Patentable Subject Matter/Industrial Applicability: JPO	32
2 Patentable Subject Matter: The EPO's Case Law	39
3 The Person Skilled in the Art: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	78
3.1 The Person Skilled in the Art: EPO	78
3.2 The Person Skilled in the Art: US	79
3.3 The Person Skilled in the Art: JPO	81
4 The Person Skilled in the Art: The EPO's Case Law	83
5 Corrections and Amendments: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	86
5.1 Corrections and Amendments: EPO (Article 123 and Rule 88 EPC1973/Rule 139 EPC2000)	86
5.2 Corrections and Amendments: US	91
5.3 Corrections and Amendments: JPO	96
6 Corrections and Amendments: The EPO's Case Law	102
7 Clarity of Claims: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	196
7.1 Clarity of Claims: EPO (Article 84 EPC)	196
7.2 Clarity of Claims: US	199
7.3 Clarity of Claims: JPO	202
8 Clarity of claims: The EPO's Case Law	204
9 Enabling Disclosure: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	240
9.1 Enabling Disclosure: EPO (Article 83 EPC)	240
9.2 Enabling Disclosure: US	250
9.3 Enabling Disclosure: JPO	265

Contents – Summary

10	Enabling disclosure: The EPO's Case Law	273
11	Deposit: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	407
11.1	Deposit: EPO (Article 83 EPC and Rule 28 and Rule 28a EPC1973/Rules 31 to 34 EPC2000 of the Implementing Regulations)	407
11.2	Deposit: US	412
11.3	Deposit: JPO	415
12	Deposit: The EPO's Case Law	417
13	Priority: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	430
13.1	Priority: EPO (Articles 87 to 89 EPC)	430
13.2	Priority: US	436
13.3	Priority: JPO	446
14	Priority: The EPO's Case Law	449
15	Novelty: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	492
15.1	Novelty: EPO (Article 54 EPC/Article 54 EPC2000)	492
15.2	Novelty: US	508
15.3	Novelty: JPO	521
16	Novelty: The EPO's Case Law	528
17	Inventive Step: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	682
17.1	Inventive Step: EPO (Article 56 EPC)	682
17.2	Inventive Step: US	694
17.3	Inventive Step: JPO	711
18	Inventive Step: The EPO's Case Law	720
19	Decisions of the EPO Dealing with Procedural Issues and Procedural Changes Due to EPC2000	1029
20	Drafting Claims for a European Patent Application	1100
21	Examples of Claims for a US Patent Application	1102
22	Examples of Claims for a Japanese Patent Application	1113
23	How to Draft the Description of a European Patent Application in Light of EPC2000 and the Current Practice of the EPO	1122
24	How to Draft the Description of a US Patent Application	1133
25	How to Draft the Description of a Japanese Patent Application	1150

26	How to Keep Notebooks for Successful Interferences	1156
27	Extensions to Patent Term	1161
	Decisions of the EPO	1169
	Decisions on U. S. Cases	1205
	Decisions on Japanese Cases	1220
	European Statutes	1223
	Cross-Reference List Article EPC1973 → Article/Rule EPC2000	1224
	Cross-Reference List Rule EPC1973 → Rule EPC2000	1226
	U. S. Statutes	1231
	Japanese Statutes	1232
	Index	1233

Contents

Foreword	V
Preface	VII
Contributors to the Fifth Edition	XIII
Contents – Summary	XV
Introduction to the 5th Edition	1
1 Patentable Subject Matter/Industrial Applicability/Utility: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	6
1.1 Patentable Subject Matter/Industrial Applicability: EPO (Articles 52 and 53 EPC1973, Articles 52, 53 and 54(5) EPC2000, the EU Directive 98/44/EC of July 6, 1998 and its Implementation by the EPO)	6
1.2 Patentable Subject Matter/Utility: US (35 U. S. C. § 101 (1984))	20
1.3 Patentable Subject Matter/Industrial Applicability: JPO	32
2 Patentable Subject Matter: The EPO's Case Law	39
2.1 The Exclusion of Plant and Animal Varieties and the Exclusion of Stem Cell Inventions from Patent Protection in Consideration of Article 53 EPC	39
2.2 The Exclusion of »Essentially Biological Processes for the Production of Plants« from Patent Protection: T 320/87, »Hybrid plants/Lubrizol«, EP-A 4 723, OJ EPO 1990, 71, T 83/05, »Broccoli/PLANT BIOSCIENCE«, EP-B1 1 069 819	53
2.3 The Exclusion of »Essentially Biological Processes for the Production of Animals« from Patent Protection: T 19/90, »Onco-mouse/HARVARD«, EP-A 169 672, OJ EPO 1990, 476	57
2.4 The Patenting of Human DNA is not Intrinsically Unethical	57
2.5 Compounds and Discoveries, Industrial Applicability	59
2.6 The Patenting of Pharmaceutical Inventions	70
2.7 The Patenting of Diagnostic Inventions and Screening Methods	77
3 The Person Skilled in the Art: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	78
3.1 The Person Skilled in the Art: EPO	78
3.2 The Person Skilled in the Art: US	79
3.3 The Person Skilled in the Art: JPO	81
4 The Person Skilled in the Art: The EPO's Case Law	83
5 Corrections and Amendments: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	86
5.1 Corrections and Amendments: EPO (Article 123 and Rule 88 EPC1973/Rule 139 EPC2000)	86
5.2 Corrections and Amendments: US	91
5.3 Corrections and Amendments: JPO	96
6 Corrections and Amendments: The EPO's Case Law	102
6.1 T 184/91, »Glu-Gln/CELTRIX«, EP-A 169 016, G 11/91, »Glu-Gln/CELTRIX«,	

Contents

	EP-A 169 016; and T 1147/98, »Cartilage-inducing factor/CELTRIX PHARMACEUTICALS INC.«, EP-B1 169 016	102
6.2	T 161/86, »Amino acid sequence modification/ELI LILLY«, EP-A 10 421	103
6.3	T 552/91, »Chroman derivatives/MERCK«, EP-A 273 262	104
6.4	T 21/86, »Amendments/AMERICAN MONITOR CORP.«, EP-A 9 222	105
6.5	T 365/88 »Improved vectors/BIOGEN«, EP-A 41 767	106
6.6	T 449/90, »Treatment of plasma/CEDARS-SINAI«, EP-B 94 611	106
6.7	T 157/90, »Human calcitonin structural gene/CELLTECH«, EP-A 70 675	107
6.8	T 923/92, »t-PA/GENENTECH«, EP-B1 93 619, OJ EPO 1996, 564	108
6.9	T 749/94, »Erythropoietin/GENETICS INSTITUTE«, EP-B1 209 539	111
6.10	T 379/95, »Hormones/ARs«, EP-B1 160 699	112
6.11	T 1046/96, »Pertussis/LELAND STANFORD«, EP-B1 275 689	113
6.12	T 277/95, »Production of erythropoietin/GENETICS INSTITUTE«, EP-B1 411 678	114
6.13	T 656/94, »Colony-stimulating factor/KIRIN-AMGEN«, EP-B1 237 545	114
6.14	T 824/94, »LAV/INSTITUT PASTEUR«, EP-B1 178 978	115
6.15	T 138/95, »Intrapulmonary delivery/GENENTECH INC.«, EP-B1 257 956	116
6.16	T 985/95, »Treatment of infertility/NOVO NORDISK A/S«, EP-B1 300 021	116
6.17	T 289/97, »Brassica/CALGENE«, EP-B1 270 615	117
6.18	T 354/97, »Protein secretion/GENENTECH«, EP-B1 88 632	118
6.19	T 658/98, »Interferon-beta 2A/YEDA RESEARCH«, EP-A 645 542	119
6.20	T 588/95, »Chimera monoclonal antibody/RESEARCH DEVELOPMENT«, EP-B1 171 496	119
6.21	T 188/97, »NANBV/Chiron Corporation«, EP-B1 318 216	120
6.22	T 1054/97, »Insect control/AVENTIS«, EP-B1 451 878	121
6.23	T 32/97, »Deleted tk-PRV vaccines/NOVAGENE«, EP-B1 149 040	122
6.24	T 339/98, »Vitamin K-dependent proteins/ELI LILLY«, EP-B1 363 126	122
6.25	T 725/99, »Live vaccines/LELAND STANFORD JUNIOR UNIVERSITY«, EP-B1 184 086	123
6.26	T 351/98, »HIV-I/CHIRON CORPORATION«, EP-B1 181 150	124
6.27	T 239/95, »Herpes simplex viral proteins/AMERICAN CYANAMID CO.«, EP-B1 101 655	125
6.28	T 450/98, »BPI fragments/NEW YORK UNIVERSITY«, EP-B1 375 724	125
6.29	T 93/98, »TNF inhibiting protein/BASF«, EP-B1 471 701	126
6.30	T 1118/98, »Nucleic acids/DU PONT DE NEMOURS«, EP-B1 520 039	126
6.31	T 160/99, »Chlamydia/WASHINGTON«, EP-B1 264 434	127
6.32	T 232/99, »Protein production/ALUSUISSE HOLDINGS A. G.«, EP-B1 239 292	127
6.33	T 756/00, »Immunotherapy/CENTOCOR INC.«, EP-A 755 683	128
6.34	T 346/01, »Osteoporosis/NOVARTIS«, EP-A 560 723	128
6.35	T 216/96, »Process for amplifying, detecting and/or cloning nucleic acid sequences/F. HOFFMANN-LA ROCHE AG«, EP-B1 200 362	128
6.36	T 785/97, »Support-bound oligonucleotides/OXFORD GENE TECHNOLOGY LIMITED«, EP-B1 386 229	129
6.37	T 310/99, »Down Syndrome/MACRI«, EP-B1 409 956	129
6.38	T 944/99, »Pesticidal toxins/MYCOGEN CORPORATION«, EP-B1 340 948	130
6.39	T 279/00, »Asymmetric reduction process/AVECIA LTD.«, EP-B1 658 211	131
6.40	T 502/00, »Determination of an analyte/DADE«, EP-B1 492 499	131
6.41	T 608/00, »Transgenic bovine/PHARMING«, EP-B1 502 976	131
6.42	T 748/00, »Oligomer libraries/AFFYMAX«, EP-B1 604 552	132
6.43	T 1000/00, »Test device/ROCHE«, EP-B1 654 659	132
6.44	T 1228/01, »Zona pelucida antigens/ZONAGEN INC.«, EP-A 396 552	133
6.45	T 86/01, »Engineered bacteriophages/ACAMBIS«, EP-B1 552 267	135

6.46	T 98/01, »Allergenic proteins/IMMULOGIC PHARMACEUTICAL CORPORATION«, EP-B1 463 059	135
6.47	T 189/01, »IFN- β 2/IL-6R/YEDA RESEARCH AND DEVELOPMENT CO., LTD.«, EP-B1 413 908	135
6.48	T 1133/00, »Tumor suppression/UNIVERSITY OF CALIFORNIA«, EP-B1 475 623	136
6.49	T 286/01, »Humanised antibodies/CELLTECH THERAPEUTICS LTD.«, EP-B1 460 167	136
6.50	T 345/01, »Cellulose degrading enzyme/NOVOZYMES«, EP-B1 531 315	137
6.51	T 836/01, »Interferon-beta2/YEDA RESEARCH AND DEVELOPMENT CO. LTD.«, EP-A 835 661	137
6.52	T 882/01, »Protein expression system/CELLTECH«, EP-B1 651 803	137
6.53	T 1014/01, »Recombinant immunoconjugates/BRISTOL-MYERS SQUIBB CO.«, EP-B1 439 095	138
6.54	T 1100/01, »Truncated transmembrane PACE/GENETICS«, EP-B1 574 402	138
6.55	T 1080/01, »Thermostable enzyme/F. HOFFMANN-LA ROCHE«, EP-B1 258 017	139
6.56	T 161/02, »Transgenic Zea mays plants/SYNGENTA«, EP-B1 513 849	140
6.57	T 579/01, »Cytoplasmic male sterile plants/ENZA ZADEN«, EP-B1 771 523	140
6.58	T 960/02, »Transfection/TRANSKARYOTIC THERAPIES«, EP-B1 649 464	141
6.59	T 1067/02, »Changed epitopes/NOVOZYMES«, EP-B1 561 907	142
6.60	T 157/03, »Reducing blood loss/ZYMOGENETICS«, EP-B1 624 095	143
6.61	T 1050/99, »Carbonyl hydrolases/GENENCOR«, EP-B1 251 446	143
6.62	T 931/01, »Ribozyme/UNIVERSITY PATENTS«, EP-B1 291 533	144
6.63	T 877/03, »Anti-CD30 antibodies/ROCHE«, EP-B1 805 871	145
6.64	T 626/00, »Framework-mutated antibodies/WELLCOME«, EP-B1 549 581	145
6.65	T 27/04, »Japanese hepatitis C virus/CHIRON«, EP-B1 419 182	147
6.66	T 20/04, »Flt3 ligands/SCHERING«, EP-B1 699 236	147
6.67	T 1331/04, »MSF/GENETICS INSTITUTE«, EP-A 567 599	148
6.68	T 342/02 and T 462/07, »End-labeled nucleotide probe/ENZO«, EP-B1 330 221,	148
6.69	T 464/94, »Transformation of plant genetic material/NOVARTIS«, EP-B1 164 575	149
6.70	T 506/02, »Measles virus/IMPFINSTITUT«, EP-B1 780 475	149
6.71	T 1052/02, »Immunochromatographic method/PACIFIC BIOTECH«, EP-B1 466 914	150
6.72	T 937/02, »G-CSF/OSAKA BIOSCIENCE«, EP-A1 521 156	150
6.73	T 1189/02, »Homologous recombination/CELL GENESYS«, EP-B1 747 485	151
6.74	T 243/03, »Plant pathogens/MOGEN«, EP-B1 474 857	152
6.75	T 494/03, »Transgenic wheat/SYNGENTA«, EP-B1 674 715	152
6.76	T 79/04, »Prion proteins/PROTEUS«, EP-B1 616 613	153
6.77	T 94/04, »Cytokine antagonists/REGENERON«, EP-B1 726 954	153
6.78	T 168/04, »Yeast vector/YOCUM«, EP-B1 707 068	154
6.79	T 329/04, »Absorption of minerals/NESTLE«, EP-B1 1 003 532	154
6.80	T 491/04, »anti TNF- α antibody/PHARMACIA & UPJOHN«, EP-B1 492 448	155
6.81	T 500/01, »Humanized immunoglobulins/PROTEIN DESIGN LABS, INC.«, EP-B1 451 216	155
6.82	T 21/05, »CTL responses to HCV/SCRIPPS«, EP-B1 759 937	157
6.83	T 35/05, »TNF ligands/YEDA«, EP-B1 585 939	157
6.84	T 59/05 »Galactopyranosides/PROCUR«, EP-A1 873 414	158
6.85	T 248/05, »Particulate direct label/INVERNESS«, EP-B1 560 411	159
6.86	T 313/05, »Apparatus for monitoring a polymerase chain reaction/APPLERA«, EP-B1 872 562	159

Contents

6.87	T 634/05, »Factor VIII:C/NOVARTIS«, EP-B1 466 199	161
6.88	T 1470/05, »HCV T-cell epitopes/INNOGENETICS«, EP-B1 725 824	161
6.89	T 1491/05, »Gene expression/CSIRO«, EP-A1 1 071 762	162
6.90	T 1181/06, »Polyketides/STANFORD«, EP-B1 725 778	162
6.91	T 25/06, »Botulinum toxin/SOLSTICE NEUROSCIENCES«, EP-B1 1 112 082	163
6.92	T 1188/06, »Molecular evolution/BIOINVENT«, EP-B1 988 378	163
6.93	T 1497/06, »GPCR/ARENA«, EP-A1 1 580 271	164
6.94	T 1213/05, »Breast and ovarian cancer/UNIVERSITY OF UTAH«, EP-B1 705 902	164
6.95	T 1048/05, »Luciferase/PERKIN ELMER LAS«, EP-B1 610 937	167
6.96	T 582/06, »DNA mutagenesis/MAXYGEN«, EP-B1 752 008	167
6.97	T 1099/06, »Transgenic plant cells/MAX PLANCK«, EP-B1 290 799	168
6.98	T 411/02, »CTLA4 récepteur/BRISTOL-MYERS SQUIBB«, EP-B1 606 217	168
6.99	T 580/05, »Humanised antibodies/CELLTECH«, EP-B1 626 390	169
6.100	T 542/04, Soybean products/E. I. Du PONT DE NEMOURS«, EP-B1 608359	170
6.101	T 1443/04, »Regeneration of Gramineae plants/SYNGENTA«, EP-B1 332 581	171
6.102	T 725/05, »Humanized Immunoglobulins II/PDL«, EP-B1 682 040	171
6.103	T 795/06, »Botulinum neurotoxine/MERZ«, EP-B1 1 185 291	171
6.104	T 329/06, »Perfused microtissue/MIT«, EP-B1 1 064 353	172
6.105	T 405/06, »Immunoglobulins/BRUSSEL«, EP-B1 656 946	172
6.106	T 801/06, »Cancer treatment with HSV mutant/CRUSADE«, EP-B1 773 785	173
6.107	T 997/06, »Insulin preparation/NOVO NORDISK«, EP-B1 921 812	174
6.108	T 1107/06, »Botulinum toxins/ALLERGAN«, EP-B1 1 005 867	174
6.109	T 1408/06, »VEGF-related protein/GENENTECH«, EP-B1 848 755	175
6.110	T 1772/06, »Clarithromycin/ABBOTT«, EP-B1 915 899	176
6.111	T 1790/06, »Expression of a gene/ALNYLAM« (December 9, 2008), EP-B1 1 144 623	176
6.112	T 382/07, »Ethereic oils/D&W TRADING«, EP-B1 828 502	176
6.113	T 391/07, »Immunotherapy of cancer/UNIVERSITY OF PENNSYLVANIA«, EP-B1 790 835	177
6.114	T 1898/07, »Interferon Formulations/BIOGEN«, EP-B1 948 358	178
6.115	T 617/07, »Monoclonal NGF-antagonist antibodies/LAY LINE«, EP-B1 1 181 318	179
6.116	T 665/07, »Heterologous genes/EDINBURGH«, EP-B1 695 361	180
6.117	T 762/07, »Estrogen receptor/ORGANON«, EP-B1 798 378	180
6.118	T 837/07, »Diagnostic primers/INFECTIO«, EP-B1 804 616	181
6.119	T 1068/07, »Enzymatic DNA/SCRIPPS«, EP-A1 981 646	181
6.120	T 1128/07, »HIV-2 variants/QUIAGEN«, EP-B1 655 501	183
6.121	T 1331/07, »Collagen-like polymers/PROTEIN POLYMER«, EP-B1 670 848	183
6.122	T 1437/07, »Botulinum toxin for treating smooth muscle spasm/ALLERGAN«, EP-B1 1 010 431	184
6.123	T 1885/07, »Alphavirus vectors/BIOPTION«, EP-B1 753 053	184
6.124	T 1/08, »Alphaviruses/BIOPTION«, EP-B1 561 890	184
6.125	T 692/08, »Lawsonia intracellularis/BOEHRINGER«, EP-B1 843 818	185
6.126	T 1022/08, »Trifunctional reagent/MITRA«, EP-A1 1 569 690	185
6.127	T 1477/08, »ACE inhibitors/SANOFI-AVENTIS«, EP-B1 1 212 081	186
6.128	T 2351/08, »Hsp70 protein/MULTHOFF«, EP-B1 1 066 050: Recording of Oral Proceedings by a Party	186
6.129	T 1001/07, »Ointment/KAPAJ«, EP-A1 1 532 982	187
6.130	T 1644/08, »Endoglucanases/NOVOZYMES«, EP-B1 815 209	187
6.131	T 445/09, »Treatment of autoimmune diseases/GENENTECH«, EP-B1 1 176 981	188
6.132	T 783/09, »Antidiabetic combinations/NOVARTIS«, EP-B1 1 248 604	188

6.133	T 878/09, »Method for the detection of prion proteins/PROTHERICS«, EP-B1 616 613	189
6.134	T 1271/09, »Expression of a gene/ALNYLAM«, EP-B1 1 214 945	189
6.135	T 244/10, »Diagnosis autoimmune/DIAGNOSTIC HYBRIDS«, EP-A1 1 268 846	189
6.136	T 305/07, »Trisulfides/PFIZER«, EP-B1 1 095 055	190
6.137	T 1456/06, »Telomerase/GERON«, EP-B1 841 396	190
6.138	T 1172/08, »Method for determining T-cell epitopes/GENENCOR«, EP-B1 1 073 754	191
6.139	T 76/09, »Protein fragment complementation assay/ODYSSEY«, EP-A1 1 305 627	192
6.140	T 341/09, »Antibody/WELLCOME«, EP-B1 1 247 865;	193
6.141	T 583/09, »Novel genes/MILLENIUM«, EP-A1 1 194 534	193
6.142	T 1803/09, »Markers congestive heart failure/SYN.X PHARMA«, EP-A1 1 423 705	194
6.143	T 191/08, »Haemagglutinin molecule complex/NOVARTIS«, EP-B1 589 348	195
7	Clarity of Claims: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	196
7.1	Clarity of Claims: EPO (Article 84 EPC)	196
7.2	Clarity of Claims: US	199
7.3	Clarity of Claims: JPO	202
8	Clarity of claims: The EPO's Case Law	204
8.1	T 301/87, »Alpha-interferons/BIOGEN«, EP-B 32 134, OJ EPO 1990, 335 to 358	204
8.2	T 281/86, »Preprothauatin/UNILEVER«, EP-A 54 331, OJ EPO 1989, 202 to 209	205
8.3	T 181/87, »DNA transfer vector/THE REGENTS OF THE UNIVERSITY OF CALIFORNIA«, EP-A 20 251	206
8.4	T 269/87, »Prochymosin/CELLTECH«, EP-A 68 691	207
8.5	T 347/87, »Method of constructing a replicable cloning vehicle/GENENTECH«, EP-A 22 242	207
8.6	T 130/90 »Recombinant Monoclonal Antibody/UNIVERSITY OF TEXAS SYSTEM«, EP-B 68 763	208
8.7	T 391/91, »Ice nucleating/UNIVERSITY OF CALIFORNIA«, EP-A 112 342	209
8.8	T 430/92, »Growth of tulips/SUMITOMO«, EP-B1 188 933	210
8.9	T 749/94, »Erythropoietin/GENETICS INSTITUTE«, EP-B1 209 539	211
8.10	T 464/94, »Transformation of plant genetic material/NOVARTIS«, EP-B1 164 575	211
8.11	T 250/96, »Transformation/NOVARTIS«, EP-A1 429 093	212
8.12	T 277/95, »Production of erythropoietin/GENETICS INSTITUTE«, EP-B1 411 678	213
8.13	T 484/98, »Modified yeast/ELSWORTH«, EP-A 463 024	213
8.14	T 965/98, »DNA amplification/HOFFMANN-LA ROCHE«, EP-A 509 612	214
8.15	T 966/98, »DNA detection/HOFFMANN-LA ROCHE«, EP-A 502 589	215
8.16	T 188/97, »NANBV/Chiron Corporation«, EP-B1 318 216	215
8.17	»Serotonin receptor/ELI LILLY«, EP-A 449 562, OJ EPO 2001, 103	215
8.18	T 1044/99, »Ionophore antibiotics/UNGDA«, EP- 615 544	216
8.19	T 680/98, »Improved vectors II/BIOGEN«, EP-B1 41 767	216
8.20	T 822/98, »Probes/BIO-RAD«, EP-B1 246 864	217

Contents

8.21	T 239/95, »Herpes simplex viral proteins/AMERICAN CYANAMID CO.«,	218
	EP-B1 101 655	
8.22	T 64/00, »Insecticidal plant expression/MYCOGEN«, EP-B1 359 472	218
8.23	T 984/00, »Ti-plasmid vectors/MAX-PLANCK-GESELLSCHAFT«, EP-A 290	
	799	219
8.24	T 1084/00, »HIV-3 variants/INNOGENETICS«, EP-A1 657 532	220
8.25	T 397/02, »Endogenous gene expression/APPLIED RESEARCH SYS«, EP-B 505	
	500	221
8.26	T 285/01, »Bone resorption/WASHINGTON RESEARCH FOUNDATION«,	
	EP-B1 394 296	221
8.27	T 610/01, »Plant growth/LONG ASHTON RESEARCH STATION«, EP-A 703	
	983	222
8.28	T 347/02, »Neoplastic phenotype/UNIVERSITY OF CALIFORNIA«, EP-B1	
	440 744	222
8.29	T 1074/00, »Hematopoietic growth factors/GENETICS INSTITUTE«, EP-B1	
	314 705	222
8.30	T 378/02, »Analysis of polynucleotide sequences/OXFORD GENE	
	TECHNOLOGY«, EP-B1 373 203	224
8.31	T 1146/02, »Vaccines containing a saponin and a sterol/SMITHKLINE	
	BEECHAM«, EP-B1 822 831	225
8.32	T 741/03, »Treatment of diabetes/LONDON HEALTH SCIENCES«, EP-B1	
	762 890	225
8.33	T 748/04, »Bioactive factors of aloe vera plants/CARRINGTON«, EP-A1 871	
	460	225
8.34	T 843/04, »Gas driven fermentation/PRAXAIR«, EP-B1 829 534	226
8.35	T 1326/04, »Avian adenovirus vector/COMMONWEALTH CSIRO«, EP-A1	
	690 612	227
8.36	T 29/05, »PVA/BRISTOL-MYERS«, EP-A1 718 402	228
8.37	T 710/05, »NMDA oxidizing agents/THE CHILDREN'S MEDICAL CEN-	
	TER«, EP-A1 486 621	229
8.38	T 723/05, »Growth hormone/PHARMACIA AKTIEBOLAG«, EP-B1 587 858	229
8.39	T 1060/05, »Security system/CRIME SOLUTIONS«, EP-A1 1 230 392	229
8.40	T 1300/05, »RET screening assay/PROGENICS«, EP-A1 847 452	230
8.41	T 25/06, »Botulinum toxin/SOLSTICE NEUROSCIENCES«,	
	EP-B1 1 112 082	231
8.42	T 18/02, »Mutant alpha-amylase/GENENCOR«, EP-B1 689 589	231
8.43	T 412/06, »Proteinase inhibitor/MAX-PLANCK-GESELLSCHAFT ZUR	
	FOERDERUNG«, EP-A1 1 207 876	232
8.44	T 1018/06, »Ischemia detection/ISCHEMIA«, EP-A1 1 411 356	232
8.45	T 1599/06, »Mycobacterium vaccinating agent/UNIVERSITY OF CALIFOR-	
	NIA«, EP-B1 771 322	233
8.46	T 411/02, »CTLA4 receptor/BRISTOL-MYERS SQUIBB«, EP-B1 606 217	234
8.47	T 640/06, »HSV particles/BIOGEN«, EP-B1 1 135 408	234
8.48	T 936/06, »Bacteriophage preparations/NYMOX«, EP-A1 895 534	235
8.49	T 1815/06, »Pre-ligand association domain/THE GOVERNMENT OF THE	
	UNITED STATES«, EP-A1 1 263 788	235
8.50	T 449/08, »Renal clearance/U. D. TESTING«, EP-A1 817 966	236
8.51	T 692/08, »Lawsonia intracellularis/BOEHRINGER«, EP-B1 843 818	236
8.52	T 744/08, »Recovery of virus/XENOVA«, EP-B1 1 002 055	237
8.53	T 1423/08, »Medium supplement/LIFE TECHNOLOGIES«, EP-986 635	237
8.54	T 1644/08, »Endoglucanases/NOVOZYMES«, EP-B1 815 209	238
8.55	T 878/09, »Method for the detection of prion proteins/PROTHERICS«, EP-B1	
	616 613	238

8.56	T 2278/09, »Analyte capture device/ABBOTT«, EP-A1 1 369 691	239
9	Enabling Disclosure: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	240
9.1	Enabling Disclosure: EPO (Article 83 EPC)	240
9.2	Enabling Disclosure: US	250
9.3	Enabling Disclosure: JPO	265
10	Enabling disclosure: The EPO's Case Law	273
10.1	Decisions on enablement of nucleic acid and protein inventions	273
10.2	Decisions on enablement of antibody technology inventions	334
10.3	Decisions on enablement of plant inventions	355
10.4	Decisions on enablement of inventions concerning viruses and their epitopes	363
10.5	Decisions on enablement of inventions concerning microorganisms	380
10.6	Decisions on enablement of other inventions	391
11	Deposit: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	407
11.1	Deposit: EPO (Article 83 EPC and Rule 28 and Rule 28a EPC1973/Rules 31 to 34 EPC2000 of the Implementing Regulations)	407
11.2	Deposit: US	412
11.3	Deposit: JPO	415
12	Deposit: The EPO's Case Law	417
12.1	T 361/87, »Microorganisms/NABISCO«, EP-A 97 973	417
12.2	T 39/88, »Microorganisms/CPC«, EP-A 111 683	417
12.3	T 106/88, »Microorganisms/CPC«, EP-A 112 459; T 90/88, »Microorganism/MICROLIFE«, EP-A 76 953; T 239/87, »Microorganisms/NABISCO«, EP-A 98 533; T 142/93, »Antibiotics/AMERICAN CYANAMID«, EP-A 182 152	418
12.4	T 118/87, »Amylolytic enzymes/CPC«, EP-A 34 470	418
12.5	J 8/87, J 9/87, »Submitting culture deposit information/IDAHO«, EP-A 155 476	418
12.6	Examining Division, »Deposit number/ROCKEFELLER«, EP 86 90 2639.3	419
12.7	T 815/90, »Hepatitis-A virus/UNITED STATES OF AMERICA«, EP-A 196 316, G 2/93, »Sufficiency of disclosure/Culture deposit information«	419
12.8	T 886/91, »Hepatitis B virus/BIOGEN«, EP-B1 13 828	422
12.9	T 412/93, »Erythropoietin/AMGEN«, EP-B1 148 605	422
12.10	T 923/92, »t-PA/GENENTECH«, EP-B1 63 619	423
12.11	T 128/92, »Interleukin-2/AJINOMOTO«, EP-B1 0 091 539	423
12.12	T 227/97, »Protein Rib/LINDAHL«, EP-A 656 014	424
12.13	T 1147/01, »PRRS Vaccine/AKZO NOBEL N. V.«, EP-B1 610 250	424
12.14	T 328/04, »Humoral immunity/DARTMOUTH COLLEGE«, EP-B1 742 721	424
12.15	Questions and answers addressing some practical problems of deposits for European patent applications and PCT applications designating the EPO	425
13	Priority: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	430
13.1	Priority: EPO (Articles 87 to 89 EPC)	430
13.2	Priority: US	436
13.3	Priority: JPO	446

Contents

14	Priority: The EPO's Case Law	449
14.1	T 81/87, »Preprorennin/COLLABORATIVE«, EP-A 57 350, OJ EPO 1990, 250 to 259	449
14.2	T 269/87, »Prochymosin/CELLTECH«, EP-A 68 691	450
14.3	T 301/87, »Alpha-interferons/BIOGEN«, EP-B 32 134, OJ EPO 1990, 335 to 358	450
14.4	T 886/91, »Hepatitis B virus/BIOGEN«, EP-B1 13 828	450
14.5	T 296/93, »HBV antigen production/BIOGEN«, EP-B1 182 442, OJ EPO 1995, 627	451
14.6	T 65/92, »HTLV/HARVARD COLLEGE«, EP-A 151 579	452
14.7	T 207/94, »Fibroblast interferon/BIOGEN«, EP-B1 41 313	453
14.8	T 441/93, »Cloning in Kluyveromyces/GIST BROCADES«, EP-B1 96 430	454
14.9	T 413/94, »Human GM-CSF/IMMUNEX CORP.«, EP-B1 183 350	454
14.10	T 380/94, »Insect control/PGS«, EP-B1 193 259	455
14.11	T 277/95 »Production of erythropoietin/GENETICS INSTITUTE«, EP-B1 411 678	456
14.12	T 236/96, »Interleukin 1/DAINIPPON«, EP-B1 188 920	457
14.13	T 919/93, »Heat treated factor VIII/CEDARS-SINAI«, EP-B1 94 611	458
14.14	T 51/95, »Mature leukocyte interferons/HOFFMANN-LA ROCHE«, EP-B1 211 148	458
14.15	T 1112/96, »Erythropoietin production/GENETICS INSTITUTE«, EP-B1 205 564	458
14.16	T 542/95, »TNF/YEDA«, EP-B1 186 833	458
14.17	T 1147/98, »Cartilage-inducing factor/CELTRIX PHARMACEUTICALS INC.«, EP-B1 169 016	459
14.18	T 188/97, »NANBV/Chiron Corporation«, EP-B1 318 216	460
14.19	T 479/97, »Expression system/NOVARTIS«, EP-B1 353 188	460
14.20	T 351/98, »HIV-I/CHIRON CORPORATION«, EP-B1 181 150	461
14.21	T 342/98, »A. orizae/NOVOZYME«, EP-B1 238 023	462
14.22	T 93/98, »TNF inhibiting protein/BASF«, EP-B1 471 701	462
14.23	T 1099/99, »Filamentous fungi/GENENCOR«, EP-B1 215 594	464
14.24	T 216/96, »Process for amplifying, detecting and/or cloning nucleic acid sequences/F. HOFFMANN-LA ROCHE AG«, EP-B1 200 362	464
14.25	T 785/97, »Support-bound oligonucleotides/OXFORD GENE TECHNOLOGY LIMITED«, EP-B1 386 229	465
14.26	T 280/00, »Inhibin/GENENTECH«, EP-B1 222 491	465
14.27	T 120/00, »Mycobacteria/COGENT«, EP-B1 460 041	465
14.28	T 279/00, »Asymmetric reduction process/AVECIA LTD.«, EP-B1 658 211	466
14.29	T 356/00, »Mammary gland FIX intron construct/PPL«, EP-B1 396 699	466
14.30	T 552/00, »3D-MPL/SMITHKLINE«, EP-B1 689 454	467
14.31	T 1127/00, »Ribozymes/GENE SHEARS«, EP-B1 321 201	467
14.32	T 8/01, »Chimeric chain receptors/CELL GENESYS«, EP-B1 517 895	468
14.33	T 351/01, »Tissue factor protein/GENENTECH«, EP-B1 278 776	468
14.34	T 423/01, »Length polymorphisms/MAX-PLANCK-GESELLSCHAFT«, EP-B1 438 512	469
14.35	T 486/01, »IGF-1/GENENTECH, INC.«, EP-B1 597 033	470
14.36	T 1014/01, »Recombinant immunoconjugates/BRISTOL-MYERS SQUIBB CO.«, EP-B1 439 095	470
14.37	T 1080/01, »Thermostable enzyme/F. HOFFMANN-LA ROCHE«, EP-B1 258 017	471
14.38	T 1074/00, »Hematopoietic growth factors/GENETICS INSTITUTE«, EP-B1 314 705	471

14.39	T 843/03, »Human papillomavirus/THE UNIVERSITY OF ROCHESTER«, EP-A 688 227	472
14.40	T 15/01, »Mystery swine disease/SDLO«, EP-B1 587 780	472
14.41	T 20/04, »Flt3 ligands/SCHERING«, EP-B1 699 236	474
14.42	T 464/94, »Transformation of plant genetic material/NOVARTIS«, EP-B1 164 575	474
14.43	T 676/01, »Treatment of inflammation/SONORAN DESERT CHEMICALS LLC«, EP-B1 512 090	474
14.44	T 1010/01, »Acellular vaccine/MEDEVA B.V.«, EP-B1 471 726	475
14.45	T 293/04, »Lyme vaccine/BAXTER«, EP-B1 522 560	475
14.46	T 1127/03, »Wound healing/RENOVO«, EP-B1 585 242	476
14.47	T 70/05, »Apoptosis receptors/GENENTECH«, EP-A1 904 366	476
14.48	T 1399/04, »Combination therapy HCV/SCHERING«, EP-B1 956 861	477
14.49	T 562/04, »Factor VII/von Willebrand factor complex/OCTAPHARMA«, EP-B1 625 161	477
14.50	T 1190/03, »Orphan receptor/KARO BIO«, EP-B1 792 292	478
14.51	T 903/05, »Teleomerase peptides/GEMVAX«, EP-B1 1 093 381	479
14.52	T 1147/02, »Antibiotic resistance/PASTEUR«, EP-B1 639 229	480
14.53	T 1213/05, »Breast and ovarian cancer/UNIVERSITY OF UTAH«, EP-B1 705 902	480
14.54	T 250/06, »Opioid receptor genes/UNIVERSITY OF CALIFORNIA«, EP-B1 656 007	481
14.55	T 1380/05, »Protein stabilization/NOVOZYMES«, EP-B1 353 250	483
14.56	T 80/05, »Method of diagnosis/UNIVERSITY OF UTAH«, EP-B1 699 754	483
14.57	T 666/05, »Mutation/UNIVERSITY OF UTAH«, EP-B1 705 903	483
14.58	T 1127/06, »Beta-amyloid peptide/ELAN«, EP-B1 736 106	484
14.59	T 1338/06, »Microarray/LELAND STANFORD JUNIOR UNIVERSITY«, EP-B1 804 731	485
14.60	T 331/07, »Negative-strand RNA virus/CONZELMANN«, EP-B1 702 085	486
14.61	T 382/07, »Ethereic oils/D&W TRADING«, EP-B1 828 502	487
14.62	T 415/07, »Ribosomal display/DISCERNA LTD.«, EP-B1 985 032	488
14.63	T 156/08, »BRCA2/UNIVERSITY OF UTAH«, EP-A1 1 260 520	488
14.64	T 1834/09, »Apo-2DcR/GENENTECH«, EP-A1 1 032 661	489
14.65	T 146/07, »Prenatal diagnosis/ISIS«, EP-B1 994 963	490
15	Novelty: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	492
15.1	Novelty: EPO (Article 54 EPC/Article 54 EPC2000)	492
15.2	Novelty: US	508
15.3	Novelty: JPO	521
16	Novelty: The EPO's Case Law	528
16.1	Decisions on Novelty for Protein Inventions	528
16.2	Decisions on Novelty for DNA Sequence Inventions	560
16.3	Decisions on Novelty of Inventions Relating to Systems for the Expression of DNA Sequences	575
16.4	Decisions on Novelty for Plasmid Inventions	588
16.5	Decisions on Novelty for Inventions on Antibody Technology	591
16.6	Decisions on Novelty for Plant and Animal Related Inventions	604
16.7	Viruses and Their Epitopes	616
16.8	PCR and Other in vitro Nucleic Acid Amplification and Detection Methods	630
16.9	Microorganisms and How to Modify Them	640

Contents

16.10	Other Decisions on Novelty	649
17	Inventive Step: Legal Basis, Summary and Discussion of the EPO, US and JPO Practice	682
17.1	Inventive Step: EPO (Article 56 EPC)	682
17.2	Inventive Step: US	694
17.3	Inventive Step: JPO	711
18	Inventive Step: The EPO's Case Law	720
18.1	Decisions on Inventive Step for Protein Inventions (Including Inventions Relating to Methods for the Preparation of Proteins and their Use)	720
18.2	Decisions on Inventive Step for Nucleic Acid (Sequence) Inventions	774
18.3	Decisions on Inventive Step of Inventions Relating to Systems for the Expression of DNA Sequences	833
18.4	Decisions on Inventive Step for Plasmid Inventions	864
18.5	Decisions on Inventive Step for Inventions on Antibody Technology	867
18.6	Decisions on Inventive Step for Plant and Animal related Inventions	897
18.7	Viruses and Their Epitopes	923
18.8	PCR and Other in vitro Nucleic Acid Amplification and Detection Methods	958
18.9	Microorganisms and How to Modify Them	970
18.10	Other Decisions on Inventive Step	984
19	Decisions of the EPO Dealing with Procedural Issues and Procedural Changes Due to EPC2000	1029
19.1	Substantive Examination: General	1029
19.2	Opposition Proceedings: Introduction of New Grounds	1041
19.3	Opposition Proceedings: The Filing of New Claim Requests	1045
19.4	Opposition Proceedings: The Filing of New Documents/Experimental and Other Evidence and the Submission of New Arguments	1058
19.5	Opposition Proceedings: Adaption of the Description	1064
19.6	Opposition Proceedings: Third Party Intervention	1065
19.7	Opposition Proceedings: Strawman	1069
19.8	Opposition Proceedings: Substantial Procedural Violation and Failures in the Opposition Division's Decision	1071
19.9	Opposition and Appeal Proceedings: Miscellaneous	1078
20	Drafting Claims for a European Patent Application	1100
21	Examples of Claims for a US Patent Application	1102
21.1	Introduction	1102
21.2	Claims Relating to Chemical Compounds	1104
21.3	Claims Relating to DNA Sequences, Vectors, Plasmids, Host Cells, and Recombinant DNA molecules	1105
21.4	Examples of Claims Relating to Polypeptides	1106
21.5	Examples of Claims Relating to Microorganisms	1107
21.6	Examples of Claims Relating to Monoclonal Antibodies	1108
21.7	Examples of Claims Relating to Transgenic Plants and Animals	1109
21.8	Method of Treatment Claims	1111
21.9	Claims That Are Not Allowable In The U.S.	1112

22	Examples of Claims for a Japanese Patent Application	1113
22.1	Introduction	1113
22.2	Claims Relating to Chemical Compounds	1114
22.3	Claims Relating to DNA Sequences	1115
22.4	Claims Relating to Recombinant Proteins	1116
22.5	Claims Relating to Vectors and Transformants	1117
22.6	Claims Relating to Microorganisms	1117
22.7	Claims Relating to Monoclonal Antibodies	1118
22.8	Claims Relating to Transgenic Plants	1118
22.9	Claims Relating to Transgenic Animals	1119
22.10	Claims Relating to Screening Methods	1119
22.11	Claims Relating to Antagonists/Inhibitors or Agonists	1119
22.12	Claims Relating to Pharmaceutical Inventions	1120
22.13	Claims Relating to iPS	1121
23	How to Draft the Description of a European Patent Application in Light of EPC2000 and the Current Practice of the EPO	1122
23.1	The Title of the Invention	1122
23.2	The Indication of the Field of the Invention	1122
23.3	The Acknowledgment of the Prior Art	1122
23.4	The Technical Problem Underlying the Invention	1122
23.5	The Solution	1122
23.6	The Legends to the Figures	1125
23.7	Examples	1125
23.8	Sequence Listings	1125
23.9	The Abstract	1126
23.10	ONLINE FILING	1126
23.11	Unity of Invention and Divisional Applications	1127
23.12	Further Formal Issues and Changes due to EPC2000 that have to be considered when Drafting Patent Applications	1130
24	How to Draft the Description of a US Patent Application	1133
24.1	The Elements of a U. S. Patent Application	1133
24.2	Meeting the Requirements of 35 U. S. C. § 112, first paragraph	1138
25	How to Draft the Description of a Japanese Patent Application	1150
25.1	Elements of a Japanese Patent Application	1150
25.2	Title of the Invention	1150
25.3	Technical Field	1150
25.4	Prior Art	1150
25.5	Problems to be Solved by the Invention	1151
25.6	Means for Solving the Problems	1151
25.7	Effects of the Invention	1151
25.8	Mode for Carrying out the Invention	1152
25.9	Examples	1154
25.10	Sequence Listing	1155
25.11	Abstract	1155
26	How to Keep Notebooks for Successful Interferences	1156
26.1	Record Keeping To Establish Dates Of Invention	1156

Contents

26.2 Notebooks 1157

26.3 Electronic And Other Records Of Experiments 1159

27 Extensions to Patent Term 1161

27.1 Supplementary Protection Certificates (SPCs) for Pharmaceuticals and Plant
Protection Products in Europe 1161

27.2 Extensions to Patent Term in the US 1164

27.3 Patent Term Extensions: JPO 1167

Decisions of the EPO 1169

Decisions on U. S. Cases 1205

Decisions on Japanese Cases 1220

European Statutes 1223

Cross-Reference List Article EPC1973 → Article/Rule EPC2000 1224

Cross-Reference List Rule EPC1973 → Rule EPC2000 1226

U. S. Statutes 1231

Japanese Statutes 1232

Index 1233